Ibogaine shows promise for PTSD relief in veterans

A recent study published in Translational Psychiatry highlights the potential of ibogaine, a psychoactive substance, in alleviating symptoms of PTSD and depression among veterans. Conducted by Stanford Medicine, the study involved 30 special forces veterans with mental health conditions linked to traumatic brain injuries.

What the study found

According to the study, 23 veterans diagnosed with PTSD reported an 88% improvement in symptoms one month after receiving ibogaine treatment in Mexico. Those with depression noted an 87% improvement, while anxiety symptoms improved by 81%. Remarkably, 19 out of the 23 veterans with PTSD achieved remission within days of treatment. At a one-year follow-up, sustained remission rates were 84% for PTSD, 66% for depression, and 61% for anxiety among the 25 veterans who completed the assessment.

Regulatory context

Ibogaine remains a Schedule I controlled substance in the United States due to its potential cardiac risks. However, an executive order issued by President Donald Trump in April 2026 urged the FDA to facilitate access to psychedelic drugs, including ibogaine, for patients with major depressive and substance abuse disorders. Proponents argue that ibogaine promotes neuroplasticity and alleviates opioid withdrawal symptoms, making it a promising candidate for treating severe PTSD.

Why it matters

The study's findings offer hope for veterans and others suffering from PTSD and related mental health conditions. With 7% of veterans experiencing PTSD at some point in their lives, compared to 6% of the general population, effective treatments are crucial. The study's co-senior author, Camarin Rolle, emphasized the sustained improvements in psychiatric symptoms, which are not typically observed in conventional treatments.

Personal accounts

Patrick Flatley, a former Green Beret, shared his positive experience with ibogaine, noting immediate relief from symptoms that had plagued him for years. "My head started to tingle," Flatley said, describing a sensation of his brain being "soothed." His account underscores the potential impact of ibogaine on individuals with severe trauma histories.

The study was funded by various organizations, including the Effie and Wofford Cain Foundation and Veterans Exploring Treatment Solutions (VETS). As the VA continues to explore psychedelic therapies in 20 active clinical trials, ibogaine's role in mental health treatment remains a topic of significant interest.